Septerna Inc（SEPN）股票分析SEPNSepterna Inc

Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. It is advancing programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, both independently and with partners. The Company's Native Complex Platform is designed to enable it to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with significant unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease. It operates in the Healthcare sector.

Septerna Inc appears to be a good buy right now due to its recent strong performance, with a 1-year change of +78.65% and a current RSI of 67.99, indicating bullish momentum. The stock has surpassed analyst target prices, with several firms raising their targets significantly, such as Jones raising theirs from $43 to $62, reflecting positive sentiment. However, the main risk is the negative net income, which was -13,034,000 in Q2 2026, indicating ongoing financial challenges that investors should monitor closely.